



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

BIOCENTURY AND BAYHELIX PRESENT: THE 5TH CHINA HEALTHCARE SUMMIT

China's Globally Facing Future: Five years ago, the first China Healthcare Summit asked how the nation would build the "Bridge to Innovation." In 2018, we examine how China is now actually building the Bridge to Global Healthcare. A full two-day program highlighted by dialog among China-facing biotech innovators and their globally-facing Chinese counterparts, plus 35 "road show" presentations and a 1x1 meeting system to arrange face-to-face discussions.

DRAFT AGENDA (SUBJECT TO CHANGE)

OPENING NIGHT - MONDAY, NOVEMBER 12, 2018

- 6:00 PM TO 9:00 PM - WELCOME RECEPTION

Network with biotech CEOs and investors from China, Asia and the West.

Hosted by Pivotal China BioVenture, Nan Fung Life Sciences, BioCentury and BayHelix

DAY 1 - TUESDAY, NOVEMBER 13, 2018

Theme: Innovation & Entrepreneurship At Home And Abroad

- 8:00 AM TO 8:50 AM - REGISTRATION AND BREAKFAST NETWORKING
- 8:50 AM TO 9:00 AM - WELCOMING REMARKS
 - David Flores, President & CEO, BioCentury Inc.
 - Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners
- 9:00 AM TO 9:50 AM - **BLUE RIBBON PANEL: CHALLENGES ON THE ROAD TO GLOBALIZATION**

BayHelix convenes a special Blue Ribbon Panel to debate the mounting obstacles to globalization and their impact on China's acceleration into the international healthcare ecosystem, its access to international talent and science, and its attractiveness as a destination for Western innovators and investors.

- Kewen JIN, M.D., Managing Partner, Serica Partners (Session Chair & Moderator)
 - Tony Chen, Partner, Jones Day
 - Tao FU, President & Chief Operating Officer, Zai Lab
 - Nisa Leung, Managing Partner, Qiming Ventures
 - Bin LI, Ph.D., CEO, Ally Bridge LB Healthcare Fund
 - Lianshan ZHANG, Ph.D., SVP and President, Global R&D, Jiangsu Hengrui Medicine Co.
- 9:50 AM TO 10:05 AM - **MORNING NETWORKING BREAK**



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

- **10:05 AM TO 11:45 AM – PRESENTING COMPANIES TRACK (SESSION 1)**

Hosted by BioCentury and BayHelix

- Acepodia Inc.
- CBT Pharmaceuticals Inc.
- Insilico Medicine Inc.
- Hutchison China MediTech Ltd. (Chi-Med) (AIM/NASDAQ:HCM)
- Aslan Pharmaceuticals Ltd. (TPEX:6497; NASDAQ:ASLN)

- **10:05 AM TO 10:35 AM – BLUE RIBBON RAPPORTEUR SESSION: DOMESTIC BIOPHARMA**

In a Fireside Chat, the leader of the innovative domestic biopharma industry association responds to points raised during the China Summit's Blue Ribbon Panel: Challenges on the Road to Globalization.

- Ruilin SONG, Executive President, PHIRDA (China Pharmaceutical Innovation and Research Development Association)
- Victor Shi, Ph.D., Chairman, BayHelix & Managing Partner, Serica Partners (Moderator)

- **10:35 AM TO 11:05 AM – BLUE RIBBON RAPPORTEUR SESSION:
INTERNATIONAL BIOPHARMA**

International biopharma leaders respond to points raised during the China Summit's Blue Ribbon Panel: Challenges on the Road to Globalization.

- David Flores, President & CEO, BioCentury Inc. (Session Chair & Moderator)
- Steve Bates, CEO, BIA (BioIndustry Association)
- Wei KANG, Managing Director, RDPAC (R&D-Based Pharmaceutical Association Committee)
- Hyunsang MUK, President & CEO, KDDF (Korea Drug Development Fund)

- **11:05 AM TO 11:50 PM – CHINA'S GLOBALIZATION CHALLENGE: INCUBATING BIOTECHS**

Every nation recognizes the importance of incubating life science start-ups. But only a few succeed. The challenges are even higher for China as it races to do so in a rapidly changing landscape. What must it do to create a robust incubator ecosystem that serves both domestic and international priorities simultaneously?

- Jimmy Wei, Ph.D., Managing Partner, Pivotal bioVenture Partners China (Session Chair & Moderator)
- Laura Benjamin, Ph.D., Founder & CEO, Oncologie Ltd.
- Da LIU, Managing Director, CR-CP Life Science Fund
- Tyrone Mao, Senior Director, Scientific Innovation, JLABS@Shanghai
- Karoly Nikolich, Ph.D., CEO & Chairman, Alkahest Inc.
- Antoine Papiernik, Managing Partner, Sofinnova Partners



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

- **11:50 AM TO 1:15PM – PLENARY: PRESENTING COMPANIES: GLOBAL BIOTECH TRACK 1 (SESSION 2) AND BOXED LUNCH**

Hosted by Zai Lab Ltd., BioCentury and BayHelix

Emcee : Tao FU, President & Chief Operating Officer, Zai Lab Ltd.

- Zai Lab Ltd. (NASDAQ:ZLAB)
- Synaffix B.V.
- Arcus Biosciences Inc. (NYSE:RCUS)
- Xynomic Pharmaceuticals Inc.

- **1:20 PM TO 2:10 PM – CHINA'S GLOBALIZATION CHALLENGE: DELIVERING RARE DISEASE SOLUTIONS AT HOME AND ABROAD?**

By issuing its first national rare disease list, China has opened the door to a huge untapped market. But the pathway from clinic to reimbursement still must be built. As the market evolves, what must domestic and Western innovators do to deliver hope to patients in China? And how can Chinese biotechs make their presence felt in the global rare disease landscape?

- James Xue, Ph.D., Chairman & CEO, Canbridge Life Sciences Ltd. (Session Chair & Moderator)
- Kevin Huang, Founder & President, Chinese Organization for Rare Disorders (CORD)
- David Oxley, SVP, Business Development & Licensing, Mesoblast Ltd.
- Gonghua PAN, Co-Founder, General Manager & Chief Operating Officer, Kira Pharmaceuticals
- Thaminda Ramanayake, Director, Business Development, BioMarin Pharmaceuticals
- Bin WANG, Ph.D., Head of Business Development, Boehringer Ingelheim Biopharmaceuticals China
- Richard Yang, Founder & CEO, Reflection Biotechnologies

- **1:20 PM TO 3:00 PM – PRESENTING COMPANIES: U.K. BIOTECH TRACK (SESSION 3)**

Hosted by the BiIndustry Association (BIA), BioCentury and BayHelix

Emcee: Steve Bates, CEO, BIA

- e-Therapeutics plc (LSE:ETX)
- Crescendo Biologics Ltd.
- F-star Biotechnology Ltd.
- Scancell Holdings plc (LSE:SCLP; FSE:SCP)
- Chain Biotechnology Ltd.



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

- **2:10 PM TO 3:10 PM – CHINA’S GLOBALIZATION CHALLENGE: LEVERAGING ITS AI FUTURE**

China’s commitment to population health, artificial intelligence and machine learning give it the wherewithal to make great strides in applying technology to domestic healthcare. Can it also create digital health powerhouses on a global scale?

- Stanley Li, M.D., Founder, DXY (Session Chair)
- Andrea de Souza, Senior Director, Informatics, Eli Lilly and Company (Moderator)
- Chengming GU, M.D., VP, Medical Affairs, Greater China Region, Pfizer Inc.
- Pek Lum, Ph.D., CEO & Founder, Auransa Inc.
- Mao MAO, Ph.D., Founder & CEO, SeekIn Inc.
- Tony Zhang, Founder & CEO, LinkDoc Technology (Beijing) Co.
- Alex Zhavoronkov, Ph.D., Co-Founder & CEO, Insilico Medicine Inc.

- **3:00 PM TO 6:00 PM – PRESENTING COMPANIES: CHINA BIOTECH TRACK (SESSION 4)**

Hosted by BeiGene Ltd., BioCentury and BayHelix

Emcee: Guillaume Vignon, Ph.D., SVP, Business Development, BeiGene Ltd.

- BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160)
- Laekna Therapeutics Shanghai Co. Ltd.
- Suzhou Ribo Life Science Co. Ltd.
- Yisheng Biopharma Co. Ltd.
- Abbisko Therapeutics Co. Ltd.
- Zhejiang Teruisi Pharmaceutical Inc.
- XW Laboratories Inc.
- PhageLux Inc.
- Elpiscience Biopharmaceuticals Co. Ltd.

- **3:10 PM TO 3:40 PM – AFTERNOON NETWORKING BREAK**



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

- **3:40 PM TO 4:30 PM – CHINA’S GLOBALIZATION CHALLENGE: BUILDING THE ACADEMIC-BIOTECH NEXUS**

Global innovation has been built on the shoulders of academic institutions and biotech companies, which continue to convert new science into breakthrough treatments. The challenge is to create a clear path for assets and IP from the university into the hands of entrepreneurs. What must China’s universities, innovators and investors do to build an internationally recognized innovation engine?

- Stella Xu, Ph.D., Managing Director, Quan Capital (Session Chair & Moderator)
- Deborah Chen, Ph.D., Head of Business Development & Licensing, Drug Discovery and Development, A*STAR, Singapore
- James Huang, Managing Partner, KPCB China, and Managing Partner, Panacea Venture
- Litao ZHANG, Ph.D., VP, Leads Discovery & Optimization, Bristol-Myers Squibb Co.
- Nick Zhang, Ph.D., Chairman & CEO, Qiagen Suzhou Translational Medicine Co. Ltd.

- **4:30 PM TO 5:30 PM – WHITHER INNOVATION IN CHINA?**

In the China Summit’s 3rd Annual Heads of Research Roundtable, R&D heads and “scientist-CEOs” from China and Abroad analyze how far China has come and what it now must accomplish to meet international expectations.

- Steve Yang, Ph.D., EVP, Chief Business Officer, WuXi AppTec (Session Chair & Moderator)
- Ruth Gimeno, Ph.D., VP, Diabetes Research & Clinical Investigation, Eli Lilly and Co.
- Xiayang QIU, Ph.D., Founder, CEO & CSO, Regor Therapeutics Inc.
- Weiguo SU, Ph.D., Executive Director & CSO, Chi-Med (Hutchison China MediTech Ltd.)
- Lai WANG, Ph.D., SVP, Head of China Development, BeiGene Ltd.
- Yinxiang WANG, Ph.D., Founder & Chairman, Beijing Jacobio Pharma Co. Ltd.
- Doug Williams, Ph.D., President & CEO, Codiak BioSciences

- **6:00 PM TO 10:00 PM – 5TH ANNIVERSARY GALA DINNER AND AFTER PARTY**

Celebrate the 5th anniversary of the BioCentury-BayHelix China Healthcare Summit with fellow delegates and Shanghai life sciences leaders at our Gala Dinner and After Party.

Hosted by C-Bridge Capital, H.C. Wainwright, BioCentury and BayHelix



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

DAY 2 - WEDNESDAY, NOVEMBER 14, 2018

THEME: MANAGING FOR DOMESTIC AND GLOBAL IMPACT

- **8:00 AM TO 9:00 AM - PLENARY: HONG KONG EXCHANGE SHOWCASE (SESSION 5) AND BREAKFAST NETWORKING**

Hosted by BioCentury and BayHelix

Emcee: David Flores, CEO, BioCentury

- GenScript Biotech Corp. (HKSE: 1548)
- Lee's Pharmaceutical Holdings Ltd. (HKSE:950)
- Hua Medicine Ltd. (HKSE:2552)

- **9:00 AM TO 9:05 AM - WELCOMING REMARKS**

- **9:05 AM TO 9:45 AM - KEYNOTE: THINKING BIG ABOUT CHINA'S HEALTHCARE ECOSYSTEM**

China's ambitious population health goals require brave initiatives, innovative partnerships and the skills of players from inside and outside the country. This opening keynote sets the stage for the day's discussion about how globally facing companies can work across borders and across technologies to create a healthy China.

- Leon Wang, EVP, International, AstraZeneca

- **9:45 AM TO 10:45 AM - THE BRIDGE TO INNOVATION: LOOKING ACROSS TO 2025**

Insights Partner McKinsey & Co. delivers the key findings from its 5th exclusive China Healthcare Summit Report for conference delegates, reflecting on what must be done to complete the Bridge to Innovation and where it could lead by 2025.

- Fangning ZHANG, Partner, McKinsey & Co.

- **10:45 AM TO 11:00 AM - MORNING NETWORKING BREAK**

- **10:45 AM TO 12:05 PM - PRESENTING COMPANIES: KOREA BIOTECH TRACK (SESSION 6)**

Hosted by the Korea Drug Development Fund (KDDF), Kinhalo Ventures Korea, BioCentury and BayHelix

Emcee: Tae-erk Kim, Chief Business Officer, KDDF

- Daewoong Pharmaceutical Co. Ltd. (KSE:069620)
- Bio-Pharm Solutions
- Bioneer Corp. (KOSDAQ: 064550)
- Wellmarker Bio Co. Ltd.



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

- **11:00 AM TO 12:10 PM – VIEW FROM THE TOP: BIOPHARMA GM PERSPECTIVES**

In their 5th annual dialogue at the China Summit, general managers from the MNCs and China's emerging class of multinational biotechs share their formulas for building a profitable product mix as the market access landscape undergoes its next round of reforms.

- Aamir Malik, Senior Partner & Co-Leader, Global Pharmaceuticals and Medical Products Practice, McKinsey & Co. (Session Chair & Moderator)
- Rogier Janssens, General Manager, China, Merck Biopharma China
- Dirk Van Niekerk, General Manager, China, Boehringer Ingelheim
- Thomas Willemsen, Chairman, GSK China Investment Co. Ltd.
- Xiaobin WU, Ph.D., General Manager, China & President, BeiGene Ltd.
- Shirley Zhao, M.D., General Manager & President, China and Hong Kong, Bristol-Myers Squibb Co.

- **12:10 PM TO 1:40 PM – 9TH ANNUAL BAYHELIX AWARDS LUNCH BANQUET**

BayHelix again celebrates outstanding individuals and companies for their achievements and contributions to China's healthcare ecosystem in five categories: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; and Person of the Year.

- Victor Shi, Ph.D., Chairman, BayHelix, and Managing Partner, Serica Partners (emcee)

- **1:40 PM TO 2:30 PM – READY TO CROSS THE BRIDGE?**

As market pressures grow at home, Chinese pharma are facing the imperative to globalize. Here's how they plan to do it. Will they compete for deals with China's internationally focused biotechs? And what does it mean for cross-border dealmakers from the West?

- Kevin Li, Ph.D., Co-Founder & Managing Partner, LYZZ Capital (Session Chair & Moderator)
- Darren Ji, M.D., Ph.D., CEO, Elpiscience Biopharmaceuticals Co. Ltd.
- Peter Ji, Director, Business Development, Luoxin Pharmaceuticals
- Ivor Royston, M.D., CEO, Viracta Therapeutics Inc.
- Joan Shen, M.D., Head of R&D, I-Mab Biopharma
- Donald Wyatt, VP, Business Development, 3SBio Inc.



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

- **1:50 PM TO 4:50 PM – PRESENTING COMPANIES GLOBAL BIOTECH TRACK 2 (SESSION 7)**

Hosted by Zai Lab Ltd., BioCentury and BayHelix

Emcee: Tao FU, President & Chief Operating Officer, Zai Lab Ltd.

- Eureka Therapeutics Inc.
- Hookipa Biotech AG
- Boston Pharmaceuticals Inc.
- Codiak BioSciences Inc.
- Refuge Biotechnologies Inc.
- F1 Oncology Inc.
- Life Length S.L.
- Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT)
- MiNA Therapeutics Ltd.

- **2:30 PM TO 3:20 PM – CHINA’S GLOBALIZATION CHALLENGE: NEW MODALITIES AND ADVANCED MANUFACTURING**

In the race to lead in new therapeutic modalities like CAR T and other cell therapies, all roads run through manufacturing. But if global prowess in manufacturing is necessary, it is not sufficient. As China creates its beachhead in manufacturing, what more must it do to deliver these treatments to patients at home and abroad?

- Chelsea Zhang, Partner, Ping An Ventures (Session Chair & Moderator)
- Jie D’Elia, Ph.D., Executive Director, Business Development, Bristol-Myers Squibb Co.
- James Li, M.D., CEO, JW Therapeutics Inc.
- BG Rhee, CEO, SCM Life Sciences
- Peter Wang, VP, Manufacturing, CMAB
- Shuyuan YAO, Ph.D., VP & Head, Advanced Therapy Unit, China, WuXi AppTec
- Li ZHU, Ph.D., Chief Strategy Officer, GenScript Biotech Corp. and Nanjing Legend Biotech

- **3:20 PM TO 3:40 PM - AFTERNOON NETWORKING BREAK**



BIOCENTURY AND BAYHELIX PRESENT:

CHINA HEALTHCARE SUMMIT 2018

The Bridge to Innovation

AGENDA

- **3:40 PM TO 4:30 PM – CAPITAL MARKETS SHOWCASE: HOT MARKETS TODAY ... WHAT ABOUT TOMORROW?**

2018 is chasing records for global financing for public and private biotechs, with IPO news dominating in both Hong Kong and the U.S. But what will be the story in 2019? And how should China's biotechs be building a strategy for accessing the capital markets over the long-term, not just when the market is hot?

- Mengyu LU, Partner, Sidley Austin (Session Chair & Moderator)
- Ziyi CHEN, Executive Director & Lead China Healthcare Analyst, Goldman Sachs
- Kenny Lam, Managing Director & Head of Healthcare Asia, Global Banking, HSBC
- George Lin, EVP & CFO, Hua Medicine
- Jonathan Wang, Ph.D., Partner, OrbiMed
- Jinzi WU, Ph.D., Founder, Chairman & CEO, Ascleptis Pharma Inc.

- **4:30 PM TO 5:00 PM – INTERNATIONAL PERSPECTIVES: VOICES FROM ABROAD**

In the Summit's capstone rapporteur session, biotech leaders from the U.S., Europe and Asia reflect on what they have learned about China's prospects for leadership at home and abroad in innovation and entrepreneurship.

- Simone Fishburn, Ph.D., VP & Executive Editor, BioCentury (Session Chair & Moderator)
- Henk Joos, Ph.D., Director, Life Sciences, Healthcare & Agriculture, Agio Capital and Business Solutions
- Brad Loncar, CEO, Loncar Investments
- Kimberly Nearing, Managing Director & Head of Life Sciences, Cedrus Investments
- Peter Pack, Ph.D., CEO, Crescendo Biologics Ltd.
- Simranjit Singh, CEO, Asia, Middle East & Africa, Guardant Health Inc.

- **5:00 PM – CLOSING REMARKS**